F013 How to Approach Challenges in Hidradenitis Suppurativa Management: Strategies to Optimize Use of HS Therapies
DESCRIPTION
This session will provide guidance for the management of hidradenitis suppurativa in challenging scenarios including in the setting of multiple previous treatment failures, pregnancy, and comorbidities such as malignancy, chronic infections, and inflammatory bowel disease. Combination management strategies and therapeutic drug monitoring will be discussed. Instructive cases of HS will be presented and explored in an interactive format. Pertinent evidence from the literature will be discussed with presented case to help guide future decision-making in challenging real-life patient situations.
LEARNING OBJECTIVES
Utilize up-to-date evidence to approach challenges in the management of hidradenitis suppurativa, using a case-based format and addressing comorbidities, treatment selection, recalcitrant disease, and pregnancy.
Identify helpful combination management strategies in HS.
Describe procedures that can be done in the outpatient setting for patients with HS
SCHEDULE
9:00 AM
Procedures you can do in your office for HS
Maria Aleshin, MD, FAAD
9:15 AM
Recalcitrant HS - what to do next?
Jennifer Lin Hsiao, MD, FAAD
9:30 AM
Considering inflammatory comorbidities in HS patients
Noah Goldfarb, MD, FAAD
9:45 AM
HS in the setting of chronic infections and malignancy
Amit Garg, MD, FAAD
10:00 AM
Decision on biologic switching and therapeutic drug monitoring
Alexandra P Charrow, MD, FAAD
10:15 AM
Caring for pregnant HS patients
Katrina Lee, MD, FAAD
10:25 AM
HS and Complementary Alternative Medicine
Vivian Shi, MD, FAAD
10:35 AM
Tips to optimize HS patient visits in a busy clinic
Andrea Tesvich Murina, MD, FAAD
10:45 AM
Q&A Discussion (all faculty)
Joslyn S Kirby, MD, FAAD
DIRECTOR
Jennifer Lin Hsiao, MD, FAAD
CO-DIRECTOR
Joslyn S Kirby, MD, FAAD
SPEAKERS
Maria Aleshin, MD, FAAD
Alexandra P Charrow, MD, FAAD
Amit Garg, MD, FAAD
Noah Goldfarb, MD, FAAD
Katrina Lee, MD, FAAD
Andrea Tesvich Murina, MD, FAAD
Vivian Shi, MD, FAAD
HANDOUTS
DISCLOSURES
Maria Aleshin, MD, FAAD
Mirador – Consultant (1099 relationship)(Fees); Novartis – Advisory Board(Fees); Santa Ana Bio – Consultant (1099 relationship)(Fees); UCB – Other(Grants/Research Funding);
Alexandra P Charrow, MD, FAAD
Avalo – Consultant (1099 relationship)(Fees); Dermatology Foundation – Investigator(Grants/Research Funding); Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received), Investigator(Grants/Research Funding); Incyte Corporation – Advisory Board(Fees), Investigator(No Compensation Received); Insmed – Investigator(No Compensation Received); Insmed Incorporated – Investigator(No Compensation Received); Novartis Pharmaceuticals Corp. – Advisory Board(Fees); Q32 Bio Inc. – Consultant (1099 relationship)(No Compensation Received); Sonoma Biotherapeutics – Investigator(No Compensation Received); UCB Pharma – Advisory Board(Honoraria); Wedbush Securities – Consultant (1099 relationship)(Honoraria);
Amit Garg, MD, FAAD
AbbVie – Advisory Board(Honoraria); Almirall – Consultant (1099 relationship)(Fees); Bluefin Biomedicine – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria); Insmed Incorporated – Consultant (1099 relationship)(Honoraria); Leo Pharma – Advisory Board(Honoraria); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Honoraria); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Otsuka Pharmaceutical Co., Ltd. – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Fees); UCB – Consultant(Honoraria); Zura Bio – Consultant (1099 relationship)(Fees);
Noah Goldfarb, MD, FAAD
MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Novartis – Investigator(Grants/Research Funding); Sonoma Biotherapeutics – Consultant (1099 relationship)(Fees); UCB – Advisory Board(Fees);
Jennifer Lin Hsiao, MD, FAAD
AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Insmed – Consultant (1099 relationship)(Fees); Leo Pharma – Consultant (1099 relationship)(Fees); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees), Speaker(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); UCB – Consultant(Fees), Speaker(Fees);
Joslyn S Kirby, MD, FAAD
Incyte Corporation – Consultant (1099 relationship)(Fees), Employee (w-2 relationship)(Salary); Penn State University – Other(Patent royalties or other compensation for Intellectual Property Rights);
Katrina Lee, MD, FAAD
Incyte – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Novartis – Advisory Board(Honoraria); Novartis Pharmaceuticals Corp. – Investigator(Grants/Research Funding);
Andrea Tesvich Murina, MD, FAAD
AbbVie – Speaker(Honoraria); Amgen – Speaker(Honoraria); Botanix Pharmaceuticals – Speaker(Honoraria); Bristol-Myers Squibb – Speaker(Honoraria); Eli Lilly and Company – Speaker(Honoraria); Galderma – Speaker(Honoraria); Janssen Biotech – Speaker(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria); Leo Pharma – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria); Ortho Dermatologics – Advisory Board(Honoraria), Speaker(Honoraria); Pfizer Inc. – Speaker(Honoraria); UCB – Advisory Board(Honoraria); UCB Pharma – Speaker(Honoraria); VeraDermics Inc. – Advisory Board(Honoraria);
Vivian Shi, MD, FAAD
AbbVie – Advisory Board(Fees), Speaker(Fees); Alumis – Advisory Board(Honoraria); Aristea Therapeutics – Advisory Board(Fees); Bain Capital – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Advisory Board(Fees); Burt's Bees – Consultant(Fees); Ceraclere – Consultant (1099 relationship)(Fees); Dematology Foundation – Other(Grants/Research Funding); Demira – Advisory Board(Fees); Dermavant Sciences, Inc. – Advisory Board(Fees); Eli Lilly and Company – Advisory Board(Fees); Foundation of Atopic Dermatitis – Other(Grants/Research Funding); Galderma – Advisory Board(Fees); Genentech, Inc. – Advisory Board(Honoraria); Global Parents for Eczema Research – Consultant(No Compensation Received); GpSkin – Consultant(Fees); HS Foundation – Board of Directors(No Compensation Received); Incyte – Advisory Board(Honoraria); Incyte Corporation – Advisory Board(Honoraria); LearnHealth/LearnSkin – Other(Fees), Stockholder(Stock); Leo Pharma – Consultant (1099 relationship)(Fees); Menlo Therapeutics – Advisory Board(Fees); National Eczema Association – Consultant (1099 relationship)(Honoraria), Speaker(No Compensation Received); Novartis – Advisory Board(Fees); Pfizer Inc. – Advisory Board(Fees); Polyfins, Inc – Consultant (1099 relationship)(Fees); Regeneron – Speaker(Fees); Sanofi Genzyme – Advisory Board(Fees), Speaker(Fees); Skin Actives Scientific – Other(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees); UCB Pharma – Advisory Board(Honoraria);